|
1
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F,
Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with
or without oxaliplatin as first-line treatment in advanced
colorectal cancer. J Clin Oncol. 18:2938–2947. 2000.
|
|
2
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G,
Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by
FOLFOX6 or the reverse sequence in advanced colorectal cancer: a
randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar
|
|
4
|
Reddy GK, Gibson AD and Price N: Evolution
of FOLFOX regimens in the treatment of advanced colorectal cancer.
Clin Colorectal Cancer. 4:296–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shimizu T, Satoh T, Tamura K, Ozaki T,
Okamoto I, Fukuoka M and Nakagawa K:
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6)
in patients with refractory or advanced colorectal cancer:
post-approval Japanese population experience. Int J Clin Oncol.
12:218–223. 2007. View Article : Google Scholar
|
|
6
|
Leichman CG, Lenz HJ, Leichman L,
Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and
Danenberg PV: Quantitation of intratumoral thymidylate synthase
expression predicts for disseminated colorectal cancer response and
resistance to protracted-infusion fluorouracil and weekly
leucovorin. J Clin Oncol. 15:3223–3229. 1997.
|
|
7
|
Metzger R, Danenberg K, Leichman CG,
Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L
and Danenberg PV: High basal level gene expression of thymidine
phosphorylase (platelet-derived endothelial cell growth factor) in
colorectal tumors is associated with nonresponse to 5-fluorouracil.
Clin Cancer Res. 4:2371–2376. 1998.
|
|
8
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB and Danenberg PV: Colorectal tumors responding to
5-fluorouracil have low gene expression levels of dihydropyrimidine
dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Clin Cancer Res. 6:1322–1327. 2000.
|
|
9
|
Shirota Y, Stoehlmacher J, Brabender J,
Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg
PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict
survival for colorectal cancer patients receiving combination
oxaliplatin and fluorouracil chemotherapy. J Clin Oncol.
19:4298–4304. 2001.
|
|
10
|
Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee
JH, Roh MS, Kim DC, Park KJ, Choi HJ and Kim HJ: Prognostic value
of ERCC1, thymidylate synthase, and glutathione S-transferase pi
for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am
J Clin Oncol. 32:38–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koopman M, Venderbosch S, Nagtegaal ID,
van Krieken JH and Punt CJ: A review on the use of molecular
markers of cytotoxic therapy for colorectal cancer, what have we
learned? Eur J Cancer. 45:1935–1949. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edler D, Glimelius B, Hallström M,
Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H:
Thymidylate synthase expression in colorectal cancer: a prognostic
and predictive marker of benefit from adjuvant fluorouracil-based
chemotherapy. J Clin Oncol. 20:1721–1728. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kornmann M, Schwabe W, Sander S, Kron M,
Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H,
Häusler P, Ott K, Behnke D, Staib L, Beger HG and Link KH:
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA
expression levels: predictors for survival in colorectal cancer
patients receiving adjuvant 5-fluorouracil. Clin Cancer Res.
9:4116–4124. 2003.
|
|
14
|
Takebayashi Y, Akiyama S, Akiba S, Yamada
K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T:
Clinicopathologic and prognostic significance of an angiogenic
factor, thymidine phosphorylase, in human colorectal carcinoma. J
Natl Cancer Inst. 88:1110–1117. 1996. View Article : Google Scholar
|
|
15
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1: Gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
16
|
Yamada H, Ichikawa W, Uetake H, Shirota Y,
Nihei Z, Sugihara K and Hirayama R: Thymidylate synthase gene
expression in primary colorectal cancer and metastatic sites. Clin
Colorectal Cancer. 1:169–173. 2008. View Article : Google Scholar
|
|
17
|
Kuramochi H, Hayashi K, Uchida K, Miyakura
S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K and
Danenberg PV: 5-fluorouracil-related gene expression levels in
primary colorectal cancer and corresponding liver metastasis. Int J
Cancer. 119:522–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kobayashi H, Sugihara K, Uetake H, Higuchi
T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ,
Danenberg KD and Danenberg PV: Messenger RNA expression of TS and
ERCC1 in colorectal cancer and matched liver metastasis. Int J
Oncol. 33:1257–1262. 2008.PubMed/NCBI
|
|
19
|
Sameshima S, Tomozawa S, Kojima M, Koketsu
S, Motegi K, Horikoshi H, Okada T, Kon Y and Sawada T:
5-Fluorouracil-related gene expression in primary sites and hepatic
metastases of colorectal carcinomas. Anticancer Res. 28:1477–1481.
2008.PubMed/NCBI
|
|
20
|
Lord RV, Salonga D, Danenberg KD, Peters
JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P,
DeMeester SR, Bremner CG, Tsai PI and Danenberg PV: Telomerase
reverse transcriptase expression is increased early in the
Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J
Gastrointest Surg. 4:135–142. 2000.PubMed/NCBI
|
|
21
|
Midgley R and Kerr D: Colorectal cancer.
Lancet. 353:391–399. 1999. View Article : Google Scholar
|
|
22
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, Tabah-Fisch I and de Gramont A; Multicenter
International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the
Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators.
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for
colon cancer. N Engl J Med. 350:2343–2351. 2004.
|
|
23
|
Raymond E, Faivre S, Woynarowski JM and
Chaney SG: Oxaliplatin: mechanism of action and antineoplastic
activity. Semin Oncol. 25:4–12. 1998.PubMed/NCBI
|
|
24
|
Gossage L and Madhusudan S: Current status
of excision repair cross complementing-group 1 (ERCC1) in cancer.
Cancer Treat Rev. 33:565–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arnould S, Hennebelle I, Canal P, Bugat R
and Guichard S: Cellular determinants of oxaliplatin sensitivity in
colon cancer cell lines. Eur J Cancer. 39:112–119. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Inokuchi M, Uetake H, Shirota Y, Yamada H,
Tajima M and Sugihara K: Gene expression of 5-fluorouracil
metabolic enzymes in primary colorectal cancer and corresponding
liver metastasis. Cancer Chemother Pharmacol. 53:391–396. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Okumura K, Shiomi H, Mekata E, Kaizuka M,
Endo Y, Kurumi Y and Tani T: Correlation between chemosensitivity
and mRNA expression level of 5-fluorouracil-related metabolic
enzymes during liver metastasis of colorectal cancer. Oncol Rep.
15:875–882. 2006.
|
|
28
|
Fujii R, Seshimo A and Kameoka S:
Relationships between the expression of thymidylate synthase,
dihydropyrimidine dehydrogenase, and orotate
phosphoribosyltransferase and cell proliferative activity and
5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin
Oncol. 8:72–78. 2003. View Article : Google Scholar
|
|
29
|
Kinoshita M, Kodera Y, Hibi K, Nakayama G,
Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M and Nakao A: Gene
expression profile of 5-fluorouracil metabolic enzymes in primary
colorectal cancer: potential as predictive parameters for response
to fluorouracil-based chemotherapy. Anticancer Res. 27:851–856.
2007.
|
|
30
|
Mori K, Hasegawa M, Nishida M, Toma H,
Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YS, Chung K,
Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M,
Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi
S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H,
Nakashima Y and Manabe T: Expression levels of thymidine
phosphorylase and dihydropyrimidine dehydrogenase in various human
tumor tissues. Int J Oncol. 17:33–38. 2000.PubMed/NCBI
|
|
31
|
Uchida K, Danenberg PV, Danenberg KD and
Grem JL: Thymidylate synthase, dihydropyrimidine dehydrogenase,
ERCC1, and thymidine phosphorylase gene expression in primary and
metastatic gastrointestinal adenocarcinoma tissue in patients
treated on a phase I trial of oxaliplatin and capecitabine. BMC
Cancer. 8:3862008. View Article : Google Scholar
|
|
32
|
Collie-Duguid ES, Johnston SJ, Boyce L,
Smith N, Cowieson A, Cassidy J, Murray GI and McLeod HL: Thymidine
phosphorylase and dihydropyrimidine dehydrogenase protein
expression in colorectal cancer. Int J Cancer. 94:297–301. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adam R, Delvart V, Pascal G, Valeanu A,
Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F,
Ghémard O, Levi F and Bismuth H: Rescue surgery for unresectable
colorectal liver metastases downstaged by chemotherapy: a model to
predict long-term survival. Ann Surg. 240:644–657. 2004.PubMed/NCBI
|
|
34
|
Folprecht G, Grothey A, Alberts S, Raab HR
and Köhne CH: Neoadjuvant treatment of unresectable colorectal
liver metastases: correlation between tumour response and resection
rates. Ann Oncol. 16:1311–1319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kabbinavar FF, Hambleton J, Mass RD,
Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of
efficacy: the addition of bevacizumab to fluorouracil/leucovorin
improves survival for patients with metastatic colorectal cancer. J
Clin Oncol. 23:3706–3712. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saltz LB, Meropol NJ, Loehrer PJ Sr,
Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in
patients with refractory colorectal cancer that expresses the
epidermal growth factor receptor. J Clin Oncol. 22:1201–1208. 2004.
View Article : Google Scholar : PubMed/NCBI
|
